Sulfasalazine
Top View
- Therapeutic Class Overview Inflammatory Bowel Disease Agents
- A Prospective Double Blind Placebo Controlled Trial of Combination Disease Modifying Antirheumatic Drugs Vs
- Aminosalicylates
- Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
- The Selection and Use of Essential Medicines
- Drugs for Parasitic Infections (2013 Edition)
- Common Antibiotics
- Brand Generic Guide
- Xct Inhibitor Sulfasalazine Depletes Paclitaxel‑Resistant Tumor Cells Through Ferroptosis in Uterine Serous Carcinoma
- ICCB-L Plate (10 Mm / 3.33 Mm) ICCB-L Well Vendor ID Chemical Name
- 5-ASA) (Mesalamine, Balsalazide, Sulfasalazine
- View of the Incidence and Outcome of Severe Systemic Reactions to Sulfasalazine
- 2001 FSIS National Residue Program Blue Book
- Salazopyrin Tablet: Each Tablet Contains 500 Mg Sulfasalazine
- In Vitro to in Vivo Extrapolation for Drug-Induced Liver Injury Using a Pair Ranking Method
- Neemmc Guidelines for Tablet Crushing and Administration Via Enteral Feeding Tubes
- Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects
- Factors Influencing Response to Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis